Ipamorelin vs CJC-1295: Mechanisms and Research Differences
Meta description: Ipamorelin vs CJC-1295 , mechanism differences, half-life data, molecular specs, and why researchers combine them. Evidence-based comparison from Etched Research.
Ipamorelin and CJC-1295 are mechanistically distinct compounds that target different nodes of the growth hormone axis: Ipamorelin is a selective GH secretagogue that acts on the ghrelin/GHS-R1a receptor, while CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs. They are not interchangeable, and they are not redundant. The research interest in combining them comes from the complementary nature of their mechanisms , together, they activate the GH axis through two independent pathways simultaneously, producing synergistic GH release in published animal models.
Etched Research carries both compounds as lyophilized powder, purity-verified at ≥99% via HPLC and mass spectrometry. This article covers the mechanism, half-life, molecular characteristics, and research applications of each, and the basis for their combined use in the literature.
Ipamorelin: Mechanism and Molecular Characteristics
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide GH secretagogue. Molecular weight: 711.86 g/mol. Molecular formula: C38H49N9O5.
Its mechanism of action centers on the ghrelin receptor, formally designated the GH secretagogue receptor type 1a (GHS-R1a). Ipamorelin is a selective agonist at this receptor. The selectivity is significant: unlike earlier-generation GH secretagogues such as GHRP-2 and GHRP-6, Ipamorelin does not produce significant co-stimulation of ACTH or cortisol release in research models. It also shows minimal prolactin elevation. This selective profile makes it a cleaner research tool for isolating GH axis effects without endocrine interference from concurrent ACTH or cortisol changes.
GHS-R1a stimulation by Ipamorelin activates the phospholipase C / protein kinase C intracellular signaling cascade within somatotrophs, increasing cytoplasmic calcium and triggering GH release. The effect is dose-dependent and pulse-like , a transient GH release peak rather than sustained elevation.
Half-life of Ipamorelin in circulation is approximately 2 hours, making it a short-acting secretagogue. In research models, the GH pulse following Ipamorelin administration returns to baseline within 3 hours, consistent with its kinetic profile.
Published research has examined Ipamorelin in models of GH deficiency, muscle catabolism, and bone density. A notable paper by Raun et al. (1998) in the European Journal of Endocrinology established Ipamorelin’s selectivity profile relative to GHRP-6, demonstrating the compound’s specificity for GH release over cortisol and prolactin stimulation , a key differentiator that made it attractive for longer-term GH axis research without the HPA axis confound.
CJC-1295: Mechanism and Molecular Characteristics
CJC-1295 (without DAC) is a 30-amino-acid synthetic analog of the naturally occurring growth hormone-releasing hormone (GHRH), specifically the first 29 amino acids of endogenous GHRH with a C-terminal amide and a Gln substitution at position 8 (Ala8 variant). The “without DAC” designation refers to the absence of the Drug Affinity Complex modification , the native peptide sequence without the albumin-binding lysine derivative added in the DAC formulation.
Molecular weight (CJC-1295 without DAC): approximately 3367.97 g/mol. Molecular formula: C152H252N44O42.
CJC-1295 acts on the GHRH receptor (GHRH-R), a Gs-coupled receptor on anterior pituitary somatotrophs. Binding activates adenylyl cyclase, increases intracellular cAMP, and activates protein kinase A, ultimately leading to GH gene transcription and GH vesicle exocytosis. This pathway is distinct from the GHS-R1a pathway activated by Ipamorelin.
The half-life of CJC-1295 without DAC is approximately 30 minutes. It is rapidly cleared, producing a GH pulse comparable in duration to Ipamorelin but through a different receptor mechanism. This short half-life differentiates it from CJC-1295 with DAC, which uses albumin binding to extend half-life to 6 to 8 days.
Published GHRH analog research extends from the foundational work of Guillemin and Vale through the modern structural analog literature. CJC-1295 specifically was investigated for its improved stability relative to native GHRH(1-29), which is degraded within minutes by dipeptidyl peptidase-IV (DPP-IV). The Ala8 substitution in CJC-1295 confers resistance to DPP-IV cleavage, extending its functional half-life beyond that of unmodified GHRH.
Half-Life Comparison and Research Implications
| Parameter | Ipamorelin | CJC-1295 (No DAC) |
|—|—|—|
| Receptor | GHS-R1a (ghrelin receptor) | GHRH-R |
| Mechanism | Phospholipase C / PKC / calcium | Adenylyl cyclase / cAMP / PKA |
| Half-life | ~2 hours | ~30 minutes |
| GH pulse duration | ~3 hours | ~1-2 hours |
| Cortisol/ACTH effect | Minimal | Minimal |
| Molecular weight | 711.86 g/mol | ~3367.97 g/mol |
The kinetic differences matter in research design. Ipamorelin’s longer effective window (2-hour half-life producing ~3 hours of GH elevation) makes it useful in protocols where sustained GH pulse duration is a variable of interest. CJC-1295 without DAC’s shorter kinetic profile more closely mimics endogenous GHRH pulsatility , the hypothalamus releases GHRH in short bursts to trigger pituitary GH pulses.
For in vivo rodent studies measuring GH pulsatility, CJC-1295 without DAC more accurately models the physiological pulsatile pattern. For protocols examining net GH output over time, Ipamorelin’s longer window may be advantageous.
Why Researchers Combine Them
The combination of a GHRH analog (CJC-1295) with a GH secretagogue (Ipamorelin) represents a dual-pathway approach to GH axis stimulation. GHRH and ghrelin act synergistically at the level of the pituitary somatotroph , GHRH primes the cell via cAMP accumulation, while ghrelin receptor activation via the PKC/calcium pathway provides a second, amplifying signal. The combined effect is greater than either compound alone.
This synergy has been demonstrated in published literature. Research by Tannenbaum et al. and subsequent investigators showed that co-administration of GHRH analogs with GH secretagogues produces supra-additive GH release in rodent models. The mechanism is well-characterized: the two pathways converge at the level of GH vesicle mobilization and exocytosis, with the dual signal producing a larger and more sustained secretory event.
From a research design perspective, the combination also serves as a useful tool for saturating the GH axis in mechanistic studies. When researchers need to examine downstream IGF-1 effects, body composition changes, or tissue-level GH signaling, a robust GH pulse is necessary to produce measurable effects in the experimental timeframe. The combination protocol achieves that more consistently than either compound alone.
Frequently Asked Questions
Q: What is the main mechanism difference between Ipamorelin and CJC-1295?
A: Ipamorelin is a GH secretagogue that acts on the ghrelin receptor (GHS-R1a) via the phospholipase C / PKC / calcium pathway. CJC-1295 is a GHRH analog that acts on the GHRH receptor via adenylyl cyclase / cAMP / PKA. They activate GH release through distinct, complementary receptor systems.
Q: Which has a longer half-life, Ipamorelin or CJC-1295?
A: Ipamorelin has a longer circulating half-life of approximately 2 hours, compared to CJC-1295 without DAC at approximately 30 minutes. CJC-1295 with DAC has an extended half-life of 6 to 8 days due to its albumin-binding modification.
Q: Why do researchers combine Ipamorelin and CJC-1295?
A: The combination activates the GH axis through two independent receptor pathways simultaneously. GHRH receptor activation (CJC-1295) and ghrelin receptor activation (Ipamorelin) are synergistic at the somatotroph level, producing greater GH release than either compound alone. This is well-documented in published rodent research.
Q: What is Ipamorelin’s molecular weight?
A: Ipamorelin has a molecular weight of 711.86 g/mol. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular formula is C38H49N9O5.
Q: Does Ipamorelin elevate cortisol or ACTH?
A: Ipamorelin shows minimal cortisol or ACTH elevation in research models, which distinguishes it from earlier GH secretagogues like GHRP-2 and GHRP-6. This selective profile is documented in the Raun et al. (1998) paper in the European Journal of Endocrinology and is one of the primary reasons Ipamorelin is preferred as a GH secretagogue research tool.
Researchers investigating GH axis biology, IGF-1 signaling, or somatotroph function will find Etched Research’ Ipamorelin and CJC-1295 (without DAC) at etchedresearch.com. Both compounds are available as lyophilized powder with batch-specific COA documentation.
*All products mentioned are for research use only. Not for human consumption.*